Companies › Clinique Ovo
2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Genitourinary; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Follitropin Delta Follicle stimulating hormone receptor agonist | FSHR | Phase 2 | IVF; Low Ovarian Reserve; Infertility | Aug 2027 |
| HP-hMG (MENOPUR) Highly purified human menopausal gonadotrophin containing FSH and LH | FSHR, LHCGR | Phase 2 | IVF | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07816562 | Follitropin Delta | Phase 3 | Low Ovarian Reserve | Genitourinary | Jul 2027 |
| NCT06997900 | Follitropin Delta | Phase 2 | IVF | Genitourinary | Aug 2027 |
| NCT06997900 | HP-hMG (MENOPUR) | Phase 2 | IVF | Genitourinary | Aug 2027 |
| NCT07153367 | Follitropin Delta | Phase 2 | Infertility | Genitourinary | Dec 2027 |
Tioga Pharmaceuticals Azure Biotech Gesynta Pharma Suzhou Sanegene Bio R1 Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.